# BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

> **NCT06120283** · PHASE1 · RECRUITING · sponsor: **BeOne Medicines** · enrollment: 399 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Hormone Receptor Positive Malignant Neoplasm of Breast
- HER2-negative Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** BGB-43395
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole
- **DRUG:** Elacestrant
- **DRUG:** Anti-Diarrheal Agent

## Key facts

- **NCT ID:** NCT06120283
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 399 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120283, "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06120283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*